Integrative urology: A spectrum of complementary and alternative therapy

Urology

Volumn 56, Issue 2, 2000, Pages 185-189

  Hirsch, Irvin H ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CERNITIN; DAIDZEIN; FINASTERIDE; GENISTEIN; LYCOPENE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PYGEUM AFRICANUM EXTRACT; QUERCETIN; SABAL EXTRACT;

ALTERNATIVE MEDICINE; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIET; FEMALE; HEALTH CARE; HERBAL MEDICINE; HORMONE SUBSTITUTION; HUMAN; MALE; MEDICAL RESEARCH; ORGAN SIZE; PEAK EXPIRATORY FLOW; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; UROLOGY;

COMPLEMENTARY THERAPIES; CYSTITIS; FEMALE; HUMANS; MALE; PHILOSOPHY, MEDICAL; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; UROLOGY; VAGINITIS;

EID: 0033914726     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00610-5     Document Type: Review

References (33)

1. Eisenberg D.M., Kessler R.C., Foster C., et al. Unconventional medicine in the United States prevalence, costs, and patterns of use . N Engl J Med. 328:1993;246-252.
2. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997 results of a follow-up national survey . JAMA. 280:1998;1569-1575.
3. Lowe F.C., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia an update . Urology. 53:1999;671-678.
4. Yip I., Heber D., Aronson W. Nutrition and prostate cancer. Urol Clin North Am. 26:1999;403-411.
5. Woolf S.H., Bell H.S., Berman B. Clinical practice guidelines in complementary and alternative medicine - an analysis of opportunities and obstacles. Arch Fam Med. 6:1997;149-154.
6. Lowe F. What I tell patients about phytotherapeutic agents for benign prostatic hyperplasia. AUA News. 3:1998;12.
7. Mitropoulos D., Kiroudi A., Mitsogiannis I., et al. In-vivo effect of the lipid-stearolic extract of Serenoa repens (Permixon®) on mast cell accumulation and glandular epithelium trophism in the rat prostate. J Urol. 16:1999;362A.
8. Epstein J.I., Partin A.W., Simon I., et al. Prostate tissue effects of Saw Palmetto extract in men with symptomatic BPH. J Urol. 161:1999;362A.
9. Vacherot F., Azzouz M., Gil-Diez de Medina S., et al. Effect of Permixon® on apoptosis and proliferation in the prostate of patients with BPH. J Urol. 161:1999;362A.
10. Descotes J.L., Rameaud J.J., Deschaseaux P., et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest. 9:1995;291-297.
11. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia a randomized international study of 1098 patients . Prostate. 29:1996;231-240.
12. Wilt T.J., Ishani A., Stark G., et al. Saw Palmetto extracts for the treatment of benign prostatic hyperplasia. JAMA. 280:1998;1604-1609.
13. Brackman F., Autet W. Once and twice daily regimens of Pygeum africanum extract a double blind study in patients with benign prostatic hyperplasia (BPH) . J Urol. 161:1999;361A.
14. Buck A.C., Rees R.W.M., Ebeling L. Treatment of chronic prostatitis and prostadynia with pollen extract. BJU. 64:1989;496-499.
15. Rugendorff E.W., Weidner W., Ebeling L., et al. Results of treatment with pollen extract (Cernilton® N) in chronic prostatitis and prostadynia. Br J Urol. 71:1993;433-438.
16. Shoskes D.A., Zeitlin S.I., Shahed A., et al. Quercetin in men with category III chronic prostatitis a preliminary prospective, double-blind, placebo-controlled trial . Urology. 54:1999;960-963.
17. Korting G., Smith S.D., Wheeler M.A., et al. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol. 161:1999;558-561.
18. Raz R., Stamm W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 329:1993;753-756.
19. Howell A.B., Vorsa N., der Marderosian A., et al. Inhibition of the adherence of P-fimbriated Escherichia coli to urothelial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med. 339:1998;1085-1086.
20. Fair W.R., Fleshner N.E., Heston W. Cancer of the prostate a nutritional disease? Urology. 50:1997;840-848.
21. Giovannucci E., Ascherio A., Rimm E.B., et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 87:1995;1767-1776.
22. Cook R.N., Stampfer M.J., Ma J., et al. β-Carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer. 86:1999;1783-1792.
23. Rao A.V., Fleshner N., Agarwal S. Serum and tissue lycopene biomarkers of oxidation in prostate cancer patients a case-controlled study . Nutr Cancer. 33:1999;159-164.
24. Messina M., Persky V., Setchell K.D.R., et al. Soy intake and cancer risk a review of in vitro and in vivo data . Nutr Cancer. 21:1994;113-131.
25. Peterson G., Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor autophosphorylation. Prostate. 22:1993;335-345.
26. Fotsis T., Pepper A.M., Aldercreutz H., et al. Genistein, a dietary-derived inhibitor of in-vitro angiogenesis. Proc Natl Acad Sci. 90:1993;2690-2694.
27. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr. 125:(suppl 3):1995;777S-783S.
28. Clark L.C., Combs G.F., Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial . JAMA. 276:1996;1957-1963.
29. Yoshizawa K., Willet W.C., Morris S.J., et al. Study of prediagnostic selenium levels in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 90:1998;1219-1234.
30. DiPaola R.S., Zhang H., Lambert H.G., et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 339:1998;785-791.
31. Halicka H.D., Ardelt B., Juan G., et al. Apoptosis and cell cycle effects inducted by extracts of the Chinese herbal preparation PC-SPES. Int J Oncol. 11:1999;437-448.
32. de la Taille A., Hayek O.R., Buttyan R., et al. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer a preliminary investigation on human cell lines and patients . BJU Int. 84:1999;845-850.
33. Nam R.K., Fleshner N., Rakovitch E., et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients. J Urol. 161:1999;1521-1524.